Get started

Approachingresistance

OPGN A Tale Of 2 FibsOPGN has slowly crept up ever since that insider buying in June. After meandering around the 786 fib line for weeks, the stock finally headed back toward that 618 fib line and...yet again...was rejected at that level. In general, momentum has been building in the stock but now with some attention, this 618 fib level could be an important one to keep an eye on for longs. You've also got the FDA review to think about as well. From June: " The company recently submitted an updated 510(k) summary to the FDA for its Acuitas AMR Gene Panel for isolates. It included all of the FDA’s previously requested updates and consistent with the FDA’s outlined timeline. OpGen was previously informed that the FDA intends to complete its review by the end of August ...Obviously, with infectious diseases taking up a lot of the news flow over the last year, diagnostics companies have grown in popularity. Along with subsidiaries Curetis GmbH and Ares Genetics GmbH, OpGen develops and commercializes molecular microbiology solutions to guide clinicians with rapid and actionable information about life-threatening infections...One of the main catalysts for this week is actually based on insider activity. A few Form 4s were filed on the 14th, showing insider buys this month. Both COO Johannes Bacher and CEO Oliver Schacht picked up a total of 40,000 shares for just over $90,000. Purchases were made at prices ranging from $2.22 to $2.30. " Quote Source & Read More: 5 Top Penny Stocks Insiders Decided To Buy In June 2021
O
by PennyStocks101
2
AMC Fib lines lining upAMC fib retraceement right now lining up with some key areas, first the 50 fib has been somewhat of a pivot over the last few sessions of consolidation. Meanwhile, this 50DMA switched to a possible resistance level late last week. Heading into the new week these will be key areas to pay attention to for longs and short alike. In addition, volume will also be important to note. Lighter volume Thursday and Friday compared to earlier in the week was the lowest since 7/12. Last week's news Adam Aaron assumed the Chairman role was seen as somewhat of a non event as it really didn't translate substantially in the market. The full AMC Entertainment Holdings, Inc. Board of Directors now includes: Adam M. Aron – Chairman of the Board and CEO; former CEO of each of Starwood Hotels and Resorts Worldwide Inc., the NBA’s Philadelphia 76ers, Vail Resorts and Norwegian Cruise Line, as well as having been the chief marketing officer of both United Airlines and Hyatt Hotels & Resorts Howard W. 'Hawk' Koch, Jr. – Movie producer, principal at The Koch Company, former president of the Academy of Motion Picture Arts and Sciences Philip Lader - Senior Advisor to Morgan Stanley Institutional Securities; formerly served as the U.S. Ambassador to the Court of St. James’s, Administrator of the U.S. Small Business Administration, White House Deputy Chief of Staff, Assistant to the President and Deputy Director of the U.S. Office of Management & Budget. Also former Chairman of WPP plc Gary F. Locke – Trade consultant and owner of Locke Global Strategies; formerly served as Governor of Washington, U.S. Secretary of Commerce, and the U.S. Ambassador to the People’s Republic of China Kathleen M. Pawlus – Retired partner of Ernst and Young, LLP having served as the Chief Financial Officer and Chief Operating Officer of its Global Assurance practice Anthony J. Saich – Director of the Ash Center for Democratic Governance and Innovation as well as Daewoo Professor of International Affairs at Harvard University’s Kennedy School of Government Adam J. Sussman – President of Epic Games; former Chief Digital Officer of Nike, Inc. Lee E. Wittlinger – Managing Director of Silver Lake; formerly an investment banker at Goldman Sachs in its Technology, Media and Telecommunications Group
NYSE:AMC
by PennyStocks101
Next Levels For NRXPFollowing up with the NRXP levels from earlier this month, it looks like before it reaches the 618 fib line, there's a pretty clear area of high traffic that has acted as both support and resistance over the last few months. That happens to sit right around the $28-$30 area. Aftermarket on Friday, NRXP failed to hold above it and settled back down just shy of $27. With 2 big volume days on the front end of this move, it will be interesting to see if this same area will act as resistance or if NRXP can firmly push back above it to possibly test the 618 fib level. Also, the 200DMA may be an interesting technical trend line to follow to see if it ultimately acts as a new support for the stock. "According to the company, 'In the recently-completed phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with ZYESAMI™ had a minimal increase in IL-6. Change in cytokine level was a prespecified endpoint of the study.'...The data were submitted to the FDA as a supplement to its pending Emergency Use Authorization application. The company has also planned on submitting a biomarker letter of intent to the FDA. NRX has explained that cytokine release syndrome or “cytokine storm” has been related to mortality in a number of conditions including Acute Respiratory Distress Syndrome. Since these data also have to do with a pending EUA application for ZYESAMI, Wednesday’s further details may be something to keep mindful of heading into the week." Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
NASDAQ:NRXP
by PennyStocks101
CIDM support vs 200DMA approaching...CIDM approaching 786 fib, which has continued to be a resistance level since last summer. It's held above this a few times, but in general, CIDM has failed to break above more times than it has successfully remained higher than this level. However, current potential support has fluctuated on the price scale but remains consistent vs the 200DMA (in red) for the last few months. "Only a few days ago, it announced that it was forgiven for a $2.2 million Paycheck Protection Program (PPP) loan. East-West Bank paid off not only the loan in full but the principal and interest of the PPP loan as well. This is a big deal and should reflect positively on the companies balance sheet moving forward. While the number may not seem that large, any debt reduction is almost always met with positive sentiment from investors. “We are very pleased to receive the notice of forgiveness of our entire PPP loan and associated interest. We remain grateful for the financial support that the CARES Act provided in response to the COVID-19 pandemic. This helped Cinedigm move into a very solid position now financially with virtually no debt and a fast-growing streaming business.” Gary Loffredo, President, and CEO of Cinedigm The sentiment from Loffredo shows that investors should keep a close eye on CIDM’s next balance sheet. Because debt is a large factor for how positively investors see a company, this massive reduction should be considered. So, with all of this in mind, is CIDM on your list of penny stocks to watch right now?" Quote Source: 7 Top Penny Stocks to Watch That You Probably Haven’t Heard Of
C
by PennyStocks101